Myelofibrosis
Explore myelofibrosis insights, conference highlights, studies and information about the treatment with momelotinib.
Not a healthcare professional? Visit our Public site
Not a healthcare professional? Visit our Public site
At GSK we are committed to improving outcomes for patients who are affected by cancer. Browse our therapeutic area sites below.
POM. Further information is available from GlaxoSmithKline (Ireland) Ltd
Adverse events should be reported directly to the Health Products Regulatory Authority (HPRA) on their website: www.hpra.ie. Adverse events should also be reported to GlaxoSmithKline on 1800 244 255 or via online form https://gsk.public.reportum.com.
▼ These medicinal products are subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.
Trade marks are owned by or licensed to the GSK group of companies.
PM-IE-ON-WCNT-260001 | January 2026